[{"orgOrder":0,"company":"Savara","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Savara","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Savara"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Jefferies"},{"orgOrder":0,"company":"Savara","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Silicon Valley Bank","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Financing","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Savara \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Hercules Capital"},{"orgOrder":0,"company":"Savara","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Solution for Nebulizer","sponsorNew":"Savara \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Jefferies"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Celerion","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Celerion"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"INC Research Limited","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Savara \/ INC Research Limited","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ INC Research Limited"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Syneos Health | Cystic Fibrosis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Syneos Health | Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Syneos Health | Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"MST-188","moa":"polymers","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"MST-188","moa":"polymers","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MST-188","moa":"polymers","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vepoloxamer","moa":"polymers","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vepoloxamer","moa":"polymers","graph1":"Nephrology","graph2":"Phase I","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ANX-188","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Schmidhofer, Mark, MD","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Schmidhofer, Mark, MD","highestDevelopmentStatusID":"7","companyTruncated":"Savara \/ Schmidhofer, Mark, MD"}]
Find Clinical Drug Pipeline Developments & Deals by Savara
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
